Cargando…
Effect of Apatinib on Serum CD4+CD25+ T cells, NK Cells, and T Cells Subgroup in Malignant Tumor
OBJECTIVE: The immune makers including CD4+CD25+ T cells, natural killer cells, and T cells subgroup were retrospectively analyzed to find the relationship between apatinib and the immune system in the patients treated with apatinib. METHOD: Forty-two patients with advanced malignant tumors orally t...
Autores principales: | Luo, Hui-Qin, He, Yi-Fu, Chen, Wen-Ju, Yan, Ying, Wu, Shu-Sheng, Hu, Xiao-Xiu, Ke, Li-Hong, Niu, Jia-Yu, Li, Hui-Min, Xu, Hui-jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997845/ https://www.ncbi.nlm.nih.gov/pubmed/31888413 http://dx.doi.org/10.1177/1533033819893667 |
Ejemplares similares
-
Effective modulation of CD4(+)CD25(+high) regulatory T and NK cells in malignant patients by combination of interferon-α and interleukin-2
por: Liu, Guangxian, et al.
Publicado: (2012) -
Proliferative capacity exhibited by human liver-resident CD49a+CD25+ NK cells
por: Martrus, Glòria, et al.
Publicado: (2017) -
CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016) -
CD4(+)CD25(+) T Cells in primary malignant hypertension related kidney injury
por: Huang, Hongdong, et al.
Publicado: (2016) -
Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
por: Pinz, Kevin G., et al.
Publicado: (2017)